Therefore, the GPER-selective agonist G-1 (CAS No. 881639-98-1) or antagonists G15 (CAS No. 1161002-05-6) and G36 (CAS No. 1392487-51-2, which displayed an improved nER counter selectivity) could be regarded as compounds of interest to modulate GBM cell growth and invasiveness [35,36,37]. Here, GPER1 is linked to glioblastoma.